BACKGROUND: In the past decade, many oncologic drugs have been approved that extend
life and/or improve patients' quality of life. However, new cancer drugs are often associated …

Fluoropyrimidines (FLs) have been widely used for more than 60 years against a range of
solid tumors and still remains the cornerstone for the treatment of colorectal, gastric, and …

Background Patients with microsatellite instability–high (MSI‐H)/mismatch repair–deficient
(dMMR) metastatic colorectal cancer (mCRC) show a significant response to checkpoint …

Background The decision to receive adjuvant chemotherapy is far from evident and remains
controversial in patients with American Joint Committee on Cancer stage II colon cancer …

Most clinical doctors rely on high-risk factors recommended by guidelines to decide whether
to undergo adjuvant chemotherapy for stage II colon cancer. However, these high-risk …

Background: Current patient selection for adjuvant chemotherapy (ACT) after curative
surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk …

Several adjuvant chemotherapy regimens exist for the treatment of stage III colon cancer. In
conjunction with the clinical data from randomized trials, cost-effectiveness studies might …

We developed a series of models to predict the likelihood of recurrence and the response to
chemotherapy for the personalized treatment of stage I and II colorectal cancer patients. A …

AIM: To compare XELOX and FOLFOX4 as colon cancer adjuvant chemotherapy based on
MOSAIC and No. 16968 trails from Chinese cost-effectiveness perspective. METHODS: A …

Background: Our aim was to evaluate the cost effectiveness of 3 months' adjuvant
chemotherapy versus 6 months in high-risk (T4 stage+ microsatellite stable) stage II colon …